Mari Mino
Harvard University
12 Papers
1.9K Citations
Mari Mino is an academic researcher from Harvard University. The author has contributed to research in topics: Bevacizumab & Vascular endothelial growth factor. The author has an hindex of 10, co-authored 12 publications.
Chat about Author
Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G. Willett,Yves Boucher,Emmanuelle di Tomaso,Dan G. Duda,Lance L. Munn,Ricky T. Tong,Daniel C. Chung,Dushyant V. Sahani,Sanjeeva P. Kalva,Sergey V. Kozin,Mari Mino,Kenneth S. Cohen,David T. Scadden,Alan C. Hartford,Alan J. Fischman,Jeffrey W. Clark,David P. Ryan,Andrew X. Zhu,Lawrence S. Blaszkowsky,Helen X. Chen,Paul C. Shellito,Gregory Y Lauwers,Rakesh K. Jain +22 more
TL;DR: It is shown that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients.
•Journal Article
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G. Willett,Yves Boucher,Emmanuelle di Tomaso,Dan G. Duda,Lance L. Munn,Ricky T. Tong,Daniel C. Chung,Dushyant V. Sahani,Sanjeeva P. Kalva,Sergey V. Kozin,Mari Mino,Kenneth S. Cohen,David T. Scadden,Alan C. Hartford,Alan J. Fischman,Jeffrey W. Clark,David P. Ryan,Andrew X. Zhu,Lawrence S. Blaszkowsky,Helen X. Chen,Paul C. Shellito,Gregory Y Lauwers,Rakesh K. Jain +22 more
TL;DR: In this article, a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients.
1.7K
Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus.
Shinichi Ban,Mari Mino,Norman S. Nishioka,William P. Puricelli,Lawrence R. Zukerberg,Michio Shimizu,Gregory Y. Lauwers +6 more
TL;DR: A systematic histopathologic evaluation allowed us to draw attention to the fact that distally located and papillary-type neoplasia seem resistant to PDT, and the higher than expected incidence of buried residual neoplastic epithelium should also be emphasized.
75
CORRIGENDUM: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G. Willett,Yves Boucher,Emmanuelle di Tomaso,Dan G. Duda,Lance L. Munn,Ricky T. Tong,Daniel C. Chung,Dushyant V. Sahani,Sanjeeva P. Kalva,Sergey V. Kozin,Mari Mino,Kenneth S. Cohen,David T. Scadden,Alan C. Hartford,Alan J. Fischman,Jeffrey W. Clark,David P. Ryan,Andrew X. Zhu,Lawrence S. Blaszkowsky,Helen X. Chen,Paul C. Shellito,Gregory Y. Lauwers,Rakesh K. Jain +22 more
TL;DR: The protocol is outlined below and the complete trial schema was omitted from the article because of a lack of time.
34
Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer
Christopher G. Willett,Daniel C. Chung,Dushyant V. Sahani,Mari Mino,Jeffrey W. Clark,David P. Ryan,Andrew X. Zhu,L. Blaszkowski,Gregory Y. Lauwers,Rakesh K. Jain +9 more
TL;DR: A phase I clinical trial is initiated to evaluate the feasibility of integrating Bevacizumab (BV - a recombinant, humanized antibody against VEGF) into a contemporary treatment program of preoperative chemotherapy and radiation therapy followed by surgery for patients with primary and non-metastatic rectal cancer.
19